Nearly two-thirds of patients with Crohn’s perianal fistulas treated with the novel stem cell–based drug darvadstrocel achieved clinical remission and had significantly improved quality of life, according to new six-month data presented at the 2022 meeting of the European Crohn’s and Colitis Organisation.
Of the patients who received darvadstrocel (Takeda), which is not yet approved for use in the United States, 65% showed clinical remission at six months in both treatment cohorts, and 73% and 74% showed a clinical response.